Peter J. Mariani - 08 Aug 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
08 Aug 2025, 19:37:21 UTC
Prior SEC filing
26 Feb 2025
Next SEC filing
16 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Peter J. Mariani

Key filing fact

Peter J. Mariani filed Form 4 for Cytosorbents Corp (CTSO) on 08 Aug 2025.

Key facts

  • This page summarizes Peter J. Mariani's Form 4 filing for Cytosorbents Corp (CTSO).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 08 Aug 2025, 19:37.

Change

  • Previous filing in this sequence was filed on 26 Feb 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001222357 Primary reporting owner

MARIANI PETER J

Relationship
Chief Financial Officer
Address
C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature
/s/ Peter J. Mariani
Signature date
08 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Award

Transaction value
$0
Shares
+71,500
Change %
+15%
Price
$0.000000
Shares after
538,113
Date
08 Aug 2025
Ownership
Direct
Footnotes
F1, F2, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTSO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+90,000
Change %
Price
$0.000000
Shares after
90,000
Date
08 Aug 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
90,000
Exercise price
$1.00
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Footnote F2

Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;

Footnote F3

(continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

Footnote F4

(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

Footnote F5

(continued from footnote 4) (d) 116,613 shares of Common Stock owned by the Reporting Person.

Footnote F6

These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .